Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Wow.
All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs ≥ 30%. No benefit with low TILs.
Unbelievable that we didn’t get to see the TILs data from KN522 yet. Hope we’ll see them soon.
Congrats Maria Vittoria Dieci!.”
You can also read.
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
